
Equillium Inc (EQ) Stock Forecast & Price Target
Equillium Inc (EQ) Analyst Ratings
Bulls say
Equillium Inc. has demonstrated a robust pipeline of innovative therapies targeting severe autoimmune and inflammatory disorders, notably through its lead candidate itolizumab, which has shown positive top-line data in the EQUALISE study for lupus nephritis, potentially enhancing its competitive positioning in the market. The possibility of Ono exercising its option presents a substantial financial boost of approximately $33 million, which would bolster the company's balance sheet and support further clinical development. Additionally, the anticipation of progressing into pivotal studies by 2025, coupled with the need for safer treatment alternatives compared to existing therapies, lays the foundation for a favorable outlook on Equillium’s stock trajectory.
Bears say
Equillium Inc. is projected to experience significant net losses, with estimates indicating a full-year 2023 net loss of $0.41 per share and a further projected net loss of $0.82 per share in 2025. Additionally, the company's 3Q23 results reflected a net loss of $0.11 per share, and the overall losses for 2023 are anticipated to reach $0.38 per share, compounding concerns about its financial health. The company also faces a reduced probability of approval for its celiac disease treatment, now estimated at only 15%, which negatively impacts its financial outlook and future revenue potential.
This aggregate rating is based on analysts' research of Equillium Inc and is not a guaranteed prediction by Public.com or investment advice.
Equillium Inc (EQ) Analyst Forecast & Price Prediction
Start investing in Equillium Inc (EQ)
Order type
Buy in
Order amount
Est. shares
0 shares